Experts discuss Prosigna-guided treatment decisions in high-risk early disease

A large-scale international study has found that an advanced genomic test can identify which breast cancer patients can avoid aggressive treatment that could harm the body.

Experts discuss Prosigna-guided treatment decisions in high-risk early disease